Skip to main content

Table 2 Characteristics of interventional studies in this systematic review and meta-analysis

From: A meta-analysis of HDL cholesterol efflux capacity and concentration in patients with rheumatoid arthritis

Authors Country Treatment Dose of drugs Study design N/female
(%)
Mean
(age)
Durationa
(year)
Length of follow-up (m) Quality
score
Outcome summary BMI
Ronda et al., 2015 [23] USA MTXc, ADAd, MTX MTX: 3–5 mg
ADA: 40 mg
One-arm study 56 (NA) 57.0 2.0 6 11 CECb was not significantly altered after RA therapy NA
P.Liao et al., 2015 [24] USA MTX, INFe,
MTX + INF
NAi One-arm study 80 (88.9) 57.0 16.5 12 13 CEC was improved in CEC after therapy Baseline: 27 ± 5
O’Neill et al., 2016 [20] UK MTX + INF,
MTX + PLAf
M + I: 5 mg/kg
M + p: 2.5–25 mg/kg
Two-arm study 18 (66.7) 58.6 5.0 12 16 CEC was not significantly altered after RA treatment Treatment: 25 ± 5
placebo: 25 ± 1
Ormseth et al., 2016 [25] USA MTX, TCZg, ADAh NA Three-arm study 59 (84.0) 53.0 9.0 6 17 CEC was not significantly altered after RA treatment NA
Ferraz-Amaro et al., 2019 [26] UK TCZ 8 mg/kg One-arm study 24 (88) 52.0 8.0 12 12 CEC was significantly increased after RA treatment Treatment: 29 ± 6
Baseline: 28 ± 5
  1. Data are presented as median (interquartile range) or mean ± SD unless otherwise indicated; a duration of RA; b cholesterol efflux capacity; c methotrexate; d adalimumab; e infliximab; f placebo; g tocilizumab; h adalimumab; i not available